Grazia Arpino1, Andrea Michelotti2, Mauro Truini3, Filippo Montemurro4, Stefania Russo5, Raffaella Palumbo6, Claudio Zamagni7, Agnese Latorre8, Dario Bruzzese9, Ferdinando Riccardi10, Michelino De Laurentiis11, Alessandra Beano12, Laura Biganzoli13, Alberto Zaniboni14, Lucio Laudadio15, Maria Malagoli16, Domenico Bilancia17, Francesco Schettini18, Mario Giuliano18, Marina Elena Cazzaniga19, Sabino De Placido18. 1. Department of Clinical Medicine and Surgery, University of Naples Federico II, Via S. Pansini 5, 80131, Naples, Italy. grazia.arpino@unina.it. 2. Medical Oncology, "Santa Chiara" Hospital, University of Pisa, Pisa, Italy. 3. Department of Pathology, National Institute for Cancer Research, Genoa, Italy. 4. Investigative Clinical Oncology, Candiolo Cancer Institute, Candiolo, Italy. 5. Medical Oncology, University Hospital, Udine, Italy. 6. Service of Preventive Oncology, IRCCS Fondazione "Salvatore Maugeri", Pavia, Italy. 7. Medical Oncology Unit, "S.Orsola-Malpighi" Hospital, Bologna, Italy. 8. National Cancer Institute, Bari, Italy. 9. Preventive Medical Sciences, University of Naples "Federico II", Naples, Italy. 10. Medical Oncology, "A. Cardarelli" Hospital, Naples, Italy. 11. National Cancer Institute Fondazione "G.Pascale", Naples, Italy. 12. Presidio Evangelico Valdese-ASL TO1, Area Medica, Turin, Italy. 13. Department of Medical Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy. 14. Department of Medical Oncology, Casa di Cura Poliambulanza, Brescia, Italy. 15. Medical Oncology, Ospedale F. Renzetti, Lanciano, Italy. 16. Oncology, Ospedali Riuniti di Trieste, Trieste, Italy. 17. Oncology, "San Carlo" Hospital, Potenza, Italy. 18. Department of Clinical Medicine and Surgery, University of Naples Federico II, Via S. Pansini 5, 80131, Naples, Italy. 19. Medical Oncology, "San Gerardo" Hospital, Monza, Italy.
Abstract
BACKGROUND: Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC. PATIENTS AND METHODS: From January to December 2012, 650 consecutive patients with HER2-positive early BC, treated in 36 different types of Italian healthcare facilities, were enrolled in this study. Age, treatment, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status were prospectively collected in these CP patients. The same data were extracted from the main adjuvant trastuzumab RCTs and pooled using the random-effects model of DerSimonian and Laird. RCT and CP patients were compared by using the Cochran Q statistics. RESULTS: Versus RCT patients, CP patients were more likely to be older than 50 years (65 vs. 49 %; p < 0.0001) and to have HR (ER and/or PgR)-positive (72 vs. 54 %; p < 0.0001) BC and less likely to have tumor >2 cm (T ≥ 2 cm 39 vs. 59 %; p < 0.0001), positive N (47 vs. 89 %; p < 0.0001) and a high G (61 vs. 67 %; p = 0.0241). CP patients more frequently received adjuvant endocrine therapy (70 vs. 57 %; p < 0.0003) and less frequently adjuvant chemotherapy (97 vs. 99.7 %; p < 0.0001). CONCLUSIONS: Most tumor and clinical features differed significantly between CP and RCT patients. These data raise concerns about the applicability of RCT results to CP patients.
BACKGROUND: Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CPpatients with HER2-positive BC. PATIENTS AND METHODS: From January to December 2012, 650 consecutive patients with HER2-positive early BC, treated in 36 different types of Italian healthcare facilities, were enrolled in this study. Age, treatment, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status were prospectively collected in these CPpatients. The same data were extracted from the main adjuvant trastuzumab RCTs and pooled using the random-effects model of DerSimonian and Laird. RCT and CPpatients were compared by using the Cochran Q statistics. RESULTS: Versus RCT patients, CPpatients were more likely to be older than 50 years (65 vs. 49 %; p < 0.0001) and to have HR (ER and/or PgR)-positive (72 vs. 54 %; p < 0.0001) BC and less likely to have tumor >2 cm (T ≥ 2 cm 39 vs. 59 %; p < 0.0001), positive N (47 vs. 89 %; p < 0.0001) and a high G (61 vs. 67 %; p = 0.0241). CPpatients more frequently received adjuvant endocrine therapy (70 vs. 57 %; p < 0.0003) and less frequently adjuvant chemotherapy (97 vs. 99.7 %; p < 0.0001). CONCLUSIONS: Most tumor and clinical features differed significantly between CP and RCT patients. These data raise concerns about the applicability of RCT results to CPpatients.
Entities:
Keywords:
Adjuvant therapy; Clinical practice; Early breast cancer; HER2; Trastuzumab
Authors: Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press Journal: J Clin Oncol Date: 2002-02-01 Impact factor: 44.544
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich Journal: Science Date: 1989-05-12 Impact factor: 47.728
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown Journal: N Engl J Med Date: 2011-10-06 Impact factor: 91.245
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon Journal: J Clin Oncol Date: 1998-08 Impact factor: 44.544
Authors: Xavier Pivot; Gilles Romieu; Marc Debled; Jean-Yves Pierga; Pierre Kerbrat; Thomas Bachelot; Alain Lortholary; Marc Espié; Pierre Fumoleau; Daniel Serin; Jean-Philippe Jacquin; Christelle Jouannaud; Maria Rios; Sophie Abadie-Lacourtoisie; Nicole Tubiana-Mathieu; Laurent Cany; Stéphanie Catala; David Khayat; Iris Pauporté; Andrew Kramar Journal: Lancet Oncol Date: 2013-06-11 Impact factor: 41.316